刘源远,陈 峰,白 玉,曲红霞,刘依凌.心悦胶囊联合替罗非班对急性心肌梗死PCI术患者心功能及心血管不良事件的影响[J].,2021,(21):4158-4162 |
心悦胶囊联合替罗非班对急性心肌梗死PCI术患者心功能及心血管不良事件的影响 |
Effect of Xinyue Capsule Combined with Tirofiban on Cardiac Function and Cardiovascular Adverse Events in Patients with Acute Myocardial Infarction Undergoing PCI |
投稿时间:2021-04-10 修订日期:2021-04-30 |
DOI:10.13241/j.cnki.pmb.2021.21.033 |
中文关键词: 心悦胶囊 替罗非班 急性心肌梗死 经皮冠状动脉介入治疗 心功能 心血管不良事件 |
英文关键词: Xinyue capsule Tirofiban Acute myocardial infarction Percutaneous coronary intervention Cardiac function Cardiovascular adverse events |
基金项目:山东省医药卫生科技发展计划项目(2016WS0370) |
|
摘要点击次数: 548 |
全文下载次数: 323 |
中文摘要: |
摘要 目的:观察心悦胶囊联合替罗非班对急性心肌梗死(AMI)经皮冠状动脉介入治疗(PCI)术患者心功能及心血管不良事件的影响。方法:选取120例行PCI术治疗的AMI患者,将其按随机信封抽签法分为对照组60例(替罗非班治疗)和研究组60例(心悦胶囊联合替罗非班治疗),对比两组疗效、临床症状改善情况、心肌肌钙蛋白I(cTnI)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、肌酸激酶同工酶(CK-MB)、脑钠肽(BNP)、不良反应、心血管不良事件发生率及预后情况。结果:对照组、研究组临床总有效率分别为75.00%(45/60)、90.00%(54/60),研究组的临床总有效率高于对照组(P<0.05)。研究组胸痛、胸闷,恶心呕吐,大汗缓解率高于对照组(P<0.05),两组心悸、气短,乏力,晕厥,大小便失禁对比无差异(P>0.05)。研究组治疗后LVEDD为(49.38±6.73)mm,LVESD为(38.14±4.35)mm,低于对照组的(55.27±5.24)mm、(43.73±5.24)mm,LVEF为(57.09±4.34)%,高于对照组的(52.63±5.33)%(P<0.05)。研究组治疗后CK-MB为(13.46±2.34)ng/mL、cTnI为(0.29±0.08)μg/L、BNP为(363.44±29.66)pg/mL,低于对照组的(24.75±2.63)ng/mL、(0.41±0.12)μg/L、(548.12±57.61)pg/mL(P<0.05)。对照组、研究组的不良反应发生率分别为8.33%(5/60)、11.67%(7/60),两组不良反应发生率对比无差异(P>0.05)。对照组、研究组的心血管不良事件发生率分别为5.00%(3/60)、16.67%(10/60),研究组的心血管不良事件发生率低于对照组(P<0.05)。结论:心悦胶囊联合替罗非班可保护行PCI术的AMI患者的心功能,减少心血管不良事件发生率,用药安全可靠,疗效明确。 |
英文摘要: |
ABSTRACT Objective: To observe the effect of Xinyue capsule combined with tirofiban on cardiac function and cardiovascular adverse events in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods: 120 patients with AMI undergoing PCI were randomly divided into control group (60 cases treated with tirofiban) and study group (60 cases treated with Xinyue capsule combined with tirofiban). The curative effect, improvement of clinical symptoms, cardiac troponin I (cTnI), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), left ventricular ejection fraction (LVEF), creatine kinase isoenzyme (CK-MB), brain natriuretic peptide (BNP), adverse reactions, incidence of cardiovascular adverse events and prognosis were compared between the two groups. Results: The clinical total effective rates of the control group and the study group were 75.00%(45/60) and 90.00% (54/60), respectively. The clinical total effective rate of the study group was higher than that of the control group(P<0.05). The remission rate of chest pain, chest tightness, nausea, vomiting and sweating in the study group was higher than that in the control group(P<0.05), but there was no difference in palpitation, shortness of breath, fatigue, syncope, fecal incontinence between the two groups(P>0.05). After treatment, LVEDD and LVESD of study group were(49.38±6.73) mm and(38.14±4.35) mm, which were lower than those of control group (55.27±5.24) mm, (43.73±5.24) mm, LVEF was (57.09±4.34)%, higher than (52.63±5.33)% (P<0.05). After treatment, CK-MB, cTnI and BNP in the study group were (13.46±2.34) ng/mL, (0.29±0.08) μg/L and (363.44±29.66) pg/mL in the study group, which were lower than those in the control group [(24.75±2.63) ng/mL, (0.41±0.12) μg/L, (548.12±57.61) pg/mL] (P<0.05). The incidence rate of adverse reactions in the control group and the study group were 8.33% (5/60) and 11.67% (7/60), respectively. There was no difference in the incidence of adverse reactions between the two groups(P>0.05). The incidence rate of cardiovascular adverse events in the control group and the study group were 5.00% (3/60) and 16.67% (10/60), respectively. The incidence rate of cardiovascular adverse events in the study group was lower than that in the control group(P<0.05). Conclusion: Xinyue capsule combined with tirofiban can protect the cardiac function of AMI patients undergoing PCI, reduce the incidence of cardiovascular adverse events, and the medication is safe and reliable with definite curative effect. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|